Therapeutic Potential of Emerging NAD plus -Increasing Strategies for Cardiovascular Diseases
Por:
Rotllan, N, Camacho, M, Tondo, M, Diarte-Anazco, EMG, Canyelles, M, Mendez-Lara, KA, Benitez, S, Alonso, N, Mauricio, D, Escola-Gil, JC, Blanco-Vaca, F, Julve, J
Publicada:
1 dic 2021
Resumen:
Cardiovascular diseases are the leading cause of death worldwide. Aging and/or metabolic stress directly impact the cardiovascular system. Over the last few years, the contributions of altered nicotinamide adenine dinucleotide (NAD+) metabolism to aging and other pathological conditions closely related to cardiovascular diseases have been intensively investigated. NAD+ bioavailability decreases with age and cardiometabolic conditions in several mammalian tissues. Compelling data suggest that declining tissue NAD+ is commonly related to mitochondrial dysfunction and might be considered as a therapeutic target. Thus, NAD+ replenishment by either genetic or natural dietary NAD+-increasing strategies has been recently demonstrated to be effective for improving the pathophysiology of cardiac and vascular health in different experimental models, as well as human health, to a lesser extent. Here, we review and discuss recent experimental evidence illustrating that increasing NAD+ bioavailability, particularly by the use of natural NAD+ precursors, may offer hope for new therapeutic strategies to prevent and treat cardiovascular diseases.
Filiaciones:
Rotllan, N:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona 08193, Spain
CIBERDEM, CIBER Diabet & Enfermedades Metabol Asociadas, Madrid 28029, Spain
Camacho, M:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
CIBERCV, CIBER Enfermedades Cardiovasc, Madrid 28029, Spain
Tondo, M:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona 08193, Spain
CIBERDEM, CIBER Diabet & Enfermedades Metabol Asociadas, Madrid 28029, Spain
Hosp Santa Creu & Sant Pau, IIB St Pau, Dept Biochem, Barcelona 08041, Spain
Diarte-Anazco, EMG:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
Canyelles, M:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona 08193, Spain
CIBERDEM, CIBER Diabet & Enfermedades Metabol Asociadas, Madrid 28029, Spain
Mendez-Lara, KA:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
Benitez, S:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
Alonso, N:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
CIBERDEM, CIBER Diabet & Enfermedades Metabol Asociadas, Madrid 28029, Spain
Hosp Badalona Germans Trias & Pujol, Dept Endocrinol & Nutr, Barcelona 08916, Spain
Mauricio, D:
CIBERDEM, CIBER Diabet & Enfermedades Metabol Asociadas, Madrid 28029, Spain
Hosp Santa Creu & Sant Pau, IIB St Pau, Dept Endocrinol & Nutr, Barcelona 08041, Spain
Escola-Gil, JC:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona 08193, Spain
CIBERDEM, CIBER Diabet & Enfermedades Metabol Asociadas, Madrid 28029, Spain
Blanco-Vaca, F:
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona 08193, Spain
CIBERDEM, CIBER Diabet & Enfermedades Metabol Asociadas, Madrid 28029, Spain
Hosp Santa Creu & Sant Pau, IIB St Pau, Dept Biochem, Barcelona 08041, Spain
Julve, J:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca & Invest Biomed, Barcelona 08041, Spain
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona 08193, Spain
CIBERDEM, CIBER Diabet & Enfermedades Metabol Asociadas, Madrid 28029, Spain
gold
|